Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| Estrogen receptor (ERα) ~70% of all breast cancers; ESR1 mutation ~30% after AI | 100% | ER+ (>=1% IHC), defining | Wikipedia |
| TROP2 | 75-90% | IHC, any expression | PMC |
| HER2 | 55-65% | HER2-low (IHC 1+ or 2+/ISH-) | Nature |
| HER3 | 50-70% | IHC, any expression | Wikipedia |
| LIV-1 (SLC39A6) Assay- and cutoff-dependent: Seagen's SGN-LIV1A programme reported far higher any-expression rates with its own IHC assay | 37-43% | IHC, high SLC39A6 expression (cytoplasmic H-score >160 in 37%; nuclear staining in 43%) in 670 unselected early breast cancers, enriched in ER+ tumours | doi.org |
| PIK3CA / PI3K-alpha | 35-40% | Activating mutation | cBioPortal (TCGA) |
| CDK4/6 Inhibitors work regardless of amplification | 15-20% | Cyclin D1 (CCND1) amplification | cBioPortal (TCGA) |
| AKT ~50% have PIK3CA/AKT1/PTEN alteration combined | 3-5% | AKT1 E17K | cBioPortal (TCGA) |
| BRCA1 / BRCA2 (HRD) BRCA2 predominant | 3-5% | Germline BRCA1/2 | Wikipedia |
| Aromatase (CYP19A1) | about 70% | Share of breast cancers that are hormone receptor-positive, the population aromatase inhibitors treat | cancer.org |
| CYP11A1 (cholesterol side-chain cleavage enzyme) | host% | Host target: first enzyme of steroid synthesis. Not a tumour alteration, so no prevalence applies; the drug acts on normal tissue or on symptoms. | |
| Progesterone receptor (PGR) | about 65-70% | Progesterone receptor-positive by immunohistochemistry | cancer.org |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
5 cell lines, 1 mouse models and 7 repositories are listed for this cancer. See them →